PT - JOURNAL ARTICLE AU - Sara Tomczyk AU - Angelina Taylor AU - Allison Brown AU - Marlieke de Kraker AU - Tim Eckmanns AU - Aiman El-Saed AU - Majid Alshamrani AU - Rene Hendriksen AU - Megan Jacob AU - Sonja Löfmark AU - Olga Perovic AU - Nandini Shetty AU - Dawn Sievert AU - Rachel Smith AU - John Stelling AU - Siddhartha Thakur AU - Barbara Tornimbene AU - Ann Christin Vietor AU - Sergey Eremin AU - on behalf of the WHO AMR Surveillance and Quality Assessment Collaborating Centre Network TI - Impact of the COVID-19 Pandemic on Antimicrobial Resistance (AMR) Surveillance, Prevention and Control: A Global Survey AID - 10.1101/2021.03.24.21253807 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.24.21253807 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21253807.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.24.21253807.full AB - Objectives The COVID-19 pandemic has had a substantial impact on health systems. The WHO Antimicrobial Resistance (AMR) Collaborating Centres Network conducted a survey to assess the effects of COVID-19 on AMR surveillance, prevention and control.Methods From October-December 2020, WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) national focal points completed a questionnaire including Likert-scales and open-ended questions. Data were descriptively analysed, income/regional differences were assessed, and free-text questions were thematically analysed.Results Seventy-three countries across income levels participated. During the COVID-19 pandemic, 67% reported limited ability to work with AMR partnerships; decreases in funding were frequently reported by low- and middle-income countries (LMICs; p<0.01). Reduced availability of nursing, medical and public health staff for AMR was reported by 71%, 69% and 64%, respectively, whereas 67% reported stable cleaning staff availability. The majority (58%) reported reduced reagents/consumables, particularly LMICs (p<0.01). Decreased numbers of cultures, elective procedures, chronically ill admissions and outpatients and increased intensive care unit admissions reported could bias AMR data. Reported overall infection prevention and control (IPC) improvement could decrease AMR rates, whereas increases in selected inappropriate IPC practices and antibiotic prescribing could increase rates. Most did not yet have complete data on changing AMR rates due to COVID-19.Conclusions This was the first survey to explore the global impact of COVID-19 on AMR among GLASS countries. Responses revealed universal patterns but also captured country variability. Although focus is understandably on COVID-19, gains in detecting and controlling AMR, a global health priority, cannot afford to be lost.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a working group belonging to the WHO AMR Surveillance and Quality Assessment Collaborating Centres Network. It was led by the coordinator of the Network at the Robert Koch Institute in Berlin, Germany, who received funding from the Global Protection Programme (GHPP) at the German Federal Ministry of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The anonymous survey was conducted as part of routine public health work by the WHO Antimicrobial Resistance (AMR) Surveillance and Quality Assessment Collaborating Centres Network. No human subjects, samples or data were involved for this research purpose. As per the policy in Germany, the survey protocol was reviewed and waived by the data protection institutional review board of the Network coordinator at Robert Koch Institute, Berlin, Germany.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe aggregated data is avaiable on a case-by-case basis upon consultation with the WHO AMR Surveillance and Quality Assessment Collaborating Centres Network coordinator (Robert Koch Institute, Berlin, Germany)